Analysts Anticipate Bio-Path Holdings, Inc. (NASDAQ:BPTH) Will Announce Earnings of -$0.46 Per Share

Equities research analysts expect Bio-Path Holdings, Inc. (NASDAQ:BPTHGet Rating) to post earnings per share (EPS) of ($0.46) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Bio-Path’s earnings. The lowest EPS estimate is ($0.52) and the highest is ($0.39). Bio-Path reported earnings per share of ($0.43) in the same quarter last year, which suggests a negative year over year growth rate of 7%. The firm is expected to announce its next earnings results on Monday, January 1st.

On average, analysts expect that Bio-Path will report full-year earnings of ($1.77) per share for the current financial year, with EPS estimates ranging from ($2.08) to ($1.45). For the next year, analysts expect that the firm will post earnings of ($1.35) per share. Zacks’ EPS averages are a mean average based on a survey of research firms that cover Bio-Path.

Bio-Path (NASDAQ:BPTHGet Rating) last issued its earnings results on Friday, March 11th. The company reported ($0.59) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.32) by ($0.27).

A number of research analysts have commented on the company. Zacks Investment Research cut Bio-Path from a “buy” rating to a “hold” rating in a research note on Monday, January 17th. assumed coverage on Bio-Path in a research note on Monday. They set a “sell” rating on the stock.

Several institutional investors and hedge funds have recently modified their holdings of the business. Citadel Advisors LLC increased its position in shares of Bio-Path by 23.1% during the second quarter. Citadel Advisors LLC now owns 25,356 shares of the company’s stock worth $169,000 after acquiring an additional 4,765 shares during the last quarter. State Street Corp purchased a new stake in shares of Bio-Path during the second quarter worth about $81,000. Morgan Stanley increased its position in shares of Bio-Path by 1,525.4% during the third quarter. Morgan Stanley now owns 21,130 shares of the company’s stock worth $108,000 after acquiring an additional 19,830 shares during the last quarter. Finally, Bailard Inc. purchased a new stake in shares of Bio-Path during the fourth quarter worth about $126,000. Institutional investors own 6.06% of the company’s stock.

Bio-Path stock traded down $0.07 during midday trading on Wednesday, reaching $3.70. The stock had a trading volume of 1,200 shares, compared to its average volume of 37,063. The stock’s 50-day simple moving average is $3.62 and its 200 day simple moving average is $4.17. The stock has a market capitalization of $26.49 million, a PE ratio of -2.40 and a beta of 1.66. Bio-Path has a twelve month low of $2.89 and a twelve month high of $8.62.

Bio-Path Company Profile (Get Rating)

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.

Recommended Stories

Get a free copy of the Zacks research report on Bio-Path (BPTH)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with's FREE daily email newsletter.